scholarly article | Q13442814 |
P50 | author | Patrik Nasr | Q86587781 |
P2093 | author name string | Mattias Ekstedt | |
Stergios Kechagias | |||
Simone Ignatova | |||
P2860 | cites work | Liver fibrosis in overweight patients | Q28145482 |
Nonalcoholic fatty liver disease: a feature of the metabolic syndrome | Q28208772 | ||
The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test | Q28282539 | ||
Design and validation of a histological scoring system for nonalcoholic fatty liver disease | Q29614930 | ||
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association | Q29617157 | ||
The natural history of nonalcoholic fatty liver disease: a population-based cohort study | Q29617161 | ||
Long-term follow-up of patients with NAFLD and elevated liver enzymes | Q29620024 | ||
Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. | Q34544284 | ||
Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? | Q34795935 | ||
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease | Q35893923 | ||
Nonalcoholic fatty liver disease: from steatosis to cirrhosis | Q36382279 | ||
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease | Q37794163 | ||
A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver | Q38105838 | ||
Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies | Q38207382 | ||
Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. | Q38447369 | ||
Nonalcoholic steatohepatitis: a study of 49 patients | Q38632482 | ||
Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. | Q38680300 | ||
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. | Q39745120 | ||
Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. | Q40084558 | ||
The natural history of nonalcoholic fatty liver: a follow-up study | Q40376691 | ||
Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States | Q41626076 | ||
Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management | Q41725283 | ||
Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up | Q42201783 | ||
Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers | Q42994550 | ||
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. | Q44527614 | ||
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection | Q44920531 | ||
The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years | Q45787554 | ||
The natural history of nonalcoholic fatty liver disease: a clinical histopathological study | Q47617617 | ||
Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. | Q51707737 | ||
Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease | Q58622754 | ||
The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD | Q61989968 | ||
Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies | Q80594561 | ||
Histological progression of non-alcoholic fatty liver disease in Chinese patients | Q81399582 | ||
Final results of a long-term, clinical follow-up in fatty liver patients | Q84384267 | ||
Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years | Q84484058 | ||
P433 | issue | 2 | |
P921 | main subject | biopsy | Q179991 |
metabolic dysfunction–associated steatotic liver disease | Q1546498 | ||
fatty liver disease | Q6058862 | ||
P304 | page(s) | 199-210 | |
P577 | publication date | 2017-12-27 | |
P1433 | published in | Hepatology Communications | Q50817751 |
P1476 | title | Natural history of nonalcoholic fatty liver disease: A prospective follow-up study with serial biopsies | |
P478 | volume | 2 |
Q64064053 | Association between ADIPOQ G276T and C11377G polymorphisms and the risk of non-alcoholic fatty liver disease: An updated meta-analysis |
Q90838502 | CON: This Patient Should Have a Noninvasive Assessment of Liver Staging |
Q60923925 | Childhood Fructoholism and Fructoholic Liver Disease |
Q60910136 | Current status, problems, and perspectives of non-alcoholic fatty liver disease research |
Q98945558 | Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data |
Q92694745 | From sugar to liver fat and public health: systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis |
Q64252579 | Glucagon-Induced Acetylation of Energy-Sensing Factors in Control of Hepatic Metabolism |
Q91966496 | Hepatocyte Deletion of Triglyceride-Synthesis Enzyme Acyl CoA: Diacylglycerol Acyltransferase 2 Reduces Steatosis Without Increasing Inflammation or Fibrosis in Mice |
Q61808847 | Identifying and Treating Nonalcoholic Fatty Liver Disease |
Q89848872 | Serum Golgi Protein 73 as a Potential Biomarker for Hepatic Necroinflammation in Population with Nonalcoholic Steatohepatitis |
Search more.